Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis CPDF
ACP J Club. 2002 Jul-Aug;137:17. doi:10.7326/ACPJC-2002-137-1-017
Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ. 2001 Nov 17;323:1151-5. [PubMed ID: 11711405]
In patients with chronic hepatitis C, is interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality?
Studies were identified by searching the controlled trials register of the Cochrane Hepato-Biliary Group, the Cochrane Library, EMBASE/Excerpta Medica, and MEDLINE (all to August 2000) and by hand searching specialist journals. Bibliographies of relevant articles were reviewed, and authors of included trials and pharmaceutical companies were contacted for unpublished studies.
Studies in any language were selected if they were randomized controlled trials comparing interferon-α plus ribavirin (combination group) with interferon-α alone in patients with chronic hepatitis C. Patients were either interferon-naive (not previously treated with interferon), relapsers (patients with a transient biochemical or virologic response to previous interferon therapy), or nonresponders (patients who did not respond to previous interferon therapy). Studies of patients with hepatitis B, HIV infection, or hepatic decompensation were excluded.
Data were extracted on study design, patient characteristics, details of the intervention, study duration, study quality, and outcomes. The primary outcome measures were virologic response (loss of detectable hepatitis C virus RNA) at the end of the treatment, 6 months after treatment, and > 6 months after treatment; liver-related morbidity (cirrhosis, hepatocellular carcinoma, and liver transplantation); and mortality.
48 trials (6585 patients) met the selection criteria. Meta-analyses were done by using random-effects models. More patients in the interferon group than in the combination group did not have a virologic response at the end of treatment (relative risk [RR] for naive patients 0.72, 95% CI 0.65 to 0.79; for relapsers 0.53, CI 0.38 to 0.74; and for nonresponders 0.83, CI 0.79 to 0.88), at 6 months after treatment (Table), and at > 6 months after treatment (RR for all patients 0.75, CI 0.62 to 0.91). The groups did not differ for liver-related morbidity and all-cause mortality.
In patients with chronic hepatitis C, interferon-α plus ribavirin is more effective than interferon-α alone for improving the hepatitis C virologic response, but not for reducing liver-related morbidity and mortality.
Sources of funding: 4 funding agencies.
For correspondence: Dr. L.K. Kjaergard, Centre for Clinical Intervention Research, Copenhagen, Denmark. E-mail email@example.com.
Table. Interferon-α plus ribavirin (IAPR) vs interferon-α (IA) for chronic hepatitis C*
|No virologic responses at 6 mo||Weighted event rates||RRR (95% CI)||NNT (CI)|
|Naive patients||64%||87%||26% (22 to 30)||5 (4 to 6)|
|Relapsers||61%||90%||33% (22 to 43)||4 (2 to 6)|
|Nonresponders||88%||98%||9% (3 to 15)||11 (7 to 30)|
*Abbreviations defined in Glossary; weighted event rates, RRR, NNT, and CI calculated from data provided by the author using random-effects models.
The review by Kjaergard and colleagues shows that for patients with chronic hepatitis C, the combination of interferon-α and ribavirin is superior to interferon-α alone in interferon-naive patients, relapsers, and nonresponders. A wide range of dosages for both interferon-α and ribavirin was used in these trials, and despite 20 years of experience with interferon-α, the optimal dosage remains unknown.
Neither interferon-α plus ribavirin nor interferon-α alone decreased hepatic morbidity or mortality in this review. This is not surprising because the post-treatment follow-up was only 6 months in most trials. In patients with compensated cirrhosis, morbidity and mortality are reduced (1).
Genotype was not considered in this meta-analysis, but response rates vary from about 20% in genotype 1 to 65% in genotype 3 (2). Conventional interferon will soon be replaced by the more efficacious pegylated interferons (3). When combined with ribavirin, they achieve sustained response rates of about 45% in genotype 1 and about 80% in genotype 3 (4). Taking into account that only 4% of patients die of hepatitis C (5) and that better treatments are on the horizon, only a small number of patients need to be treated with the essentially obsolete regimens assessed in this review.
Juerg Reichen, MD
University of Berne
1. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-72. [PubMed ID: 9024300]
2. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999;19(Suppl. 1):S57-65. [PubMed ID: 10349693]
3. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343:1666-72. [PubMed ID: 11106715]
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. [PubMed ID: 11583749]
5. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31:1014-8. [PubMed ID: 10733560]